The reasons are multifactorial: chronic inflammation damages blood vessel walls, corticosteroid use raises cholesterol and blood pressure, lupus-specific antibodies (particularly antiphospholipid antibodies) increase clotting risk, and the metabolic disruption caused by both the disease and its treatments creates a perfect storm for atherosclerosis
Healthcare systems are more focused on newer therapeutic approaches that not only control blood glucose but also target linked comorbidities
Since obesity, insulin resistance, liver fat, and metabolic dysfunction are closely linked, GLP-1 and glucagon-based combinations are being studied for their potential to reduce liver fat, improve metabolic markers, and slow disease progression
Without adequate saliva, your risk of cavities and gum disease increases substantially
Dual GIP/GLP-1 agonists: tirzepatide What it is: Tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors
GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake